Inspire Medical Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inspire Medical Systems, Inc.

Inspire Medical Systems (INSP) disclosed an elongated launch timeline for its Inspire V device due to training/onboarding shortfalls, delayed claims software updates (to early July), and excess inventory driving poor demand—leading it to cut 2025 earnings guidance by over 80% to $0.40–$0.50 per share from $2.20–$2.30. The company and certain executives are facing an ongoing federal securities class action alleging failure to disclose material information, with the case moved from SDNY to the District of Minnesota. This is a significant reputational and earnings-risk overhang for the stock.

Analysis

This is mostly a duration extension, not a new damage event. The market already knew the core commercial failure; what matters now is that legal scrutiny keeps management credibility impaired and makes every recovery metric harder to believe, which should sustain a higher equity risk premium. For a launch-dependent medtech name, that translates into slower multiple normalization even if operating results stop deteriorating.

The second-order loser is the broader implantable sleep-apnea ecosystem: physicians and centers tend to prefer the least-friction pathway after a launch misstep, so any trust break can redirect marginal patients back toward incumbent noninvasive options. That is a relative tailwind for RMD over the next 1-3 quarters, while D&O insurers, defense counsel, and plaintiff firms capture the economic value of the controversy. The real P&L risk for INSP is not a one-time settlement; it is elevated opex, slower center onboarding, and a longer payback period on salesforce and training investment.

Near term, the stock should trade on whether there is evidence that the launch infrastructure is actually fixed: clean claims processing, better center conversion, and inventory normalization. If those metrics do not improve over the next 1-2 quarters, the market can reprice INSP lower on the same facts because the issue shifts from disclosure quality to business model execution. Conversely, if management delivers two clean quarters with re-accelerating sequential revenue, the litigation overhang becomes mostly noise and the short thesis weakens materially.

Key Decisions for Investors

• Prefer long RMD vs short INSP on any post-headline relief rally over the next 1-3 months; this is a cleaner relative-value expression than an outright short because the downside in INSP is driven by credibility, not industry demand.
• Do not chase INSP on legal-news weakness alone; wait for the next quarterly update and use it as the real catalyst. If center onboarding and claims-processing metrics do not improve, treat the name as a sell-on-strength candidate.
• If options liquidity is workable, consider a short-dated INSP put spread only on a bounce that compresses implied vol; the thesis is event-driven multiple compression, not a binary litigation collapse.
• Set a falsifier around operating recovery: two consecutive quarters of sequential revenue acceleration plus stable/expanding gross margin would argue the litigation discount is fully priced and that the launch issue was one-off.
• Watch D&O and small-cap medtech peer sentiment (elective med device names with complex reimbursement/onboarding) for spillover de-rating; a broad multiple reset would make INSP vulnerable even without new company-specific disclosures.